Which genetic alterations are included in the ASCO/OH(CCO) joint guidelines for the systemic treatment of stage IV non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

In 2021, ASCO/OH(CCO) issued joint guidelines on treatment of stage IV NSCLC with alterations in any of the following molecular targets [222] :

  • Epidermal growth factor receptor ( EGFR)
  • Anaplastic lymphoma kinase ( ALK)
  • ROS1 fusions
  • BRAF V600e mutations
  • RET fusions
  • MET exon 14 skipping mutations
  • NTRK fusions

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!